Home > Insider Trading > Filing (0000059478-13-000082)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463729	Receptos Inc.	RCPT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
59478	Lilly Eli & Co	Lilly Corporate Center Indianapolis IN 46285	No	No	Yes	No
1552293	Edward S. Torres	C/O Receptos, Inc. 10835 Road To The Cure, Suite 205 San Diego CA 92121	No	No	Yes	No
1575852	Lilly Ventures Fund I Llc	C/O Receptos, Inc. 10835 Road To The Cure, Suite 205 San Diego CA 92121	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-05-14	1,152,039	$5.25	1,266,324	No	4	C	Indirect	by Group
Common Stock	Acquisiton	2013-05-14	672,029	$7.73	1,938,353	No	4	C	Indirect	by Group
Common Stock	Acquisiton	2013-05-14	142,857	$14.00	2,081,210	No	4	P	Indirect	by Group

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	by Group
No	4	C	Indirect	by Group
No	4	P	Indirect	by Group

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-05-14	0	$0.00	1,152,039	$5.25
Common Stock	Series B Preferred Stock	Disposition	2013-05-14	0	$0.00	672,029	$7.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres, is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein. The attached Exhibit 99.1 lists details for each 10% and beneficial owner.
The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration.